Litcius/Paper detail

LBA0010 EFFICACY AND SAFETY OF NIPOCALIMAB, AN ANTI-FcRn MONOCLONAL ANTIBODY, IN PRIMARY SJOGREN’S DISEASE: RESULTS FROM A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY (DAHLIAS)

J.E. Gottenberg, Kathy L. Sivils, Kim Campbell, Jada Idokogi, Kim Hung Lo, Stephanie M. Liva, Harman Dhatt, Jesse J. Hubbard, Ghaith Noaiseh

2024Annals of the Rheumatic Diseases19 citationsDOI

Topics & Concepts

MedicineAntibodyImmunologyAutoantibodyInternal medicinePlaceboAutoimmune diseaseClinical endpointClinical trialPathologyAlternative medicineSalivary Gland Disorders and FunctionsGalectins and Cancer BiologyMonoclonal and Polyclonal Antibodies Research
LBA0010 EFFICACY AND SAFETY OF NIPOCALIMAB, AN ANTI-FcRn MONOCLONAL ANTIBODY, IN PRIMARY SJOGREN’S DISEASE: RESULTS FROM A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY (DAHLIAS) | Litcius